Cortactin binds F-actin and promotes cell migration. We showed earlier that cortactin is acetylated. Here, we identify SIRT1 (a class III histone deacetylase) as a cortactin deacetylase and p300 as a cortactin acetylase. We show that SIRT1 deacetylates cortactin in vivo and in vitro and that the SIRT1 inhibitor EX-527 increases amounts of acetylated cortactin in ovarian cancer cells. We also show that p300 acetylates cortactin in vivo and that cells lacking or depleted of p300 express lessacetylated cortactin than do control cells. Deletion analysis mapped the SIRT1-binding domain of cortactin to its repeat region, which also binds F-actin. Mouse embryo fibroblasts (MEFs) lacking sir2a (the mouse homolog of SIRT1) migrated more slowly than did wildtype cells. The expression of SIRT1 in sir2a-null cells restored migratory capacity, as did expression of a deacetylation-mimetic mutant of cortactin. SIRT1 and cortactin were more abundant in breast tumor tissue than in their normal counterparts, whereas SIRT1 expression inversely correlates with the ratio of acetylation cortactin versus total cortactin. These data suggest that deacetylation of cortactin is associated with high levels of SIRT1 and tumorigenesis. Finally, breast and ovarian cancer cell lines expressing an acetylation mimetic mutant of cortactin are less motile than that of control cells, whereas cells expressing the deacetylation mimetic mutant of cortactin migrate faster than that of control cells in Transwell migration assays. In summary, our results suggest that cortactin is a novel substrate for SIRT1 and p300 and, for the first time, a possible role for SIRT1 in cell motility through deacetylation of cortactin.
Introduction
Cell migration is involved in a wide variety of physiological processes, such as embryonic development and wound healing, as well as pathological conditions, such as tumor metastasis. Cortactin, a prominent Src substrate and an F-actin-binding protein, is a key regulator of cell migration (Kanner et al., 1990; Wu et al., 1991; Wu and Parsons, 1993) . The protein sequence of cortactin contains an N-terminal acidic domain (NTA), six and a half tandem repeats of a unique 37-amino acid sequence and a Src homology 3 (SH3) domain at the C terminus (Wu et al., 1991) . Among these domains, the repeat region is necessary and sufficient to bind F-actin (Weed et al., 2000) . Between the repeats and the SH3 domain is an a-helical structure followed by a proline-rich region.
It is well established that Src phosphorylates cortactin primarily at three residues , which are located between the proline-rich and the SH3 domains, and phosphorylated cortactin are believed to promote cell migration (Huang et al., 1998) . In contrast, two extracellular signal-regulated kinase (ERK) sites located at Ser-405 and Ser-418 sites, and ERK phosphorylation enhances cortactin binding and activation of N-WASP (Huang et al., 1998; Campbell et al., 1999; Weed and Parsons, 2001; Martinez-Quiles et al., 2004) . Recent studies using mass spectrometry have identified 17 new sites of phosphorylation (12 serine, 4 threonine and 1 tyrosine), suggesting that cortactin is heavily phosphorylated in vivo (Martin et al., 2006) .
Accumulating evidence supports the notion that cortactin is involved in tumor metastasis (Buday and Downward, 2007) . The human homolog of cortactin is encoded by the gene EMS1, which is amplified at chromosome 11q13 in several types of tumors, including head and neck, liver, bladder and breast cancers (Schuuring et al., 1993; Bringuier et al., 1996; Patel et al., 1996; Yuan et al., 2003) . Increased cortactin gene copy numbers correlate with poor patient prognosis (Rodrigo et al., 2000) , suggesting that amplification of the cortactin gene directly contributes to tumor severity. In cultured fibroblasts, cortactin is mainly distributed along the leading edges of cells, for example in lamellipodia and punctuate-like structures (Bowden et al., 1999) . Overexpression of cortactin in NIH3T3 After transfection for 36 h, cell extracts were prepared and incubated overnight with GST-cortactin coupled to glutathione agarose beads. Protein-bound beads were washed extensively with lysis buffer, eluted and subjected to SDS-polyacrylamide gel electrophoresis (PAGE), followed by western blot analysis with anti-Flag antibodies (top panel). Expression of Flag-SIRT1-7 was monitored by a direct western blot with an anti-Flag antibody (lower panel). The arrow indicates the Flag-SIRT3 band. (b) 293T cells were transfected with Myc-cortactin together with empty vector, Flag-SIRT1 or Flag-SIRT2. After transfection for 36 h, cells were lysed and Myc-cortactin was pulled down by anti-Myc agarose beads, followed by a western blotting analysis with an anti-Flag antibody (upper panel). The blot was then stripped and reprobed with anti-Myc antibodies to examine the efficiency of the pull-down assays (bottom panel). A direct anti-Flag western blot analysis was performed to determine the expressions of Flag-SIRT1 and Flag-SIRT2 (middle panel). (c) 293T cell lysate was incubated with anti-Flag or anti-cortactin antibodies. Input and precipitates were analysed by western blotting using an anti-SIRT1 antibody. The blot was then stripped and reprobed with an anti-cortactin antibody.
(d) A reciprocal immunoprecipitation analysis was performed using 293T cells as panel c. (e) Top panel: A schematic diagram (not drawn to scale) of cortactin and various GST-tagged cortactin deletion mutants. The numbers in parenthesis indicate the amino acid. FL, full length; NTA, N-terminal acidic domain. Bottom panels: C13 cells were lysed in lysis buffer and were divided into five aliquots and incubated with GST, GST-FL, GST-NTA, GST-repeat and GST-C-term-coupled glutathione-agarose beads, respectively. Protein-bound beads were washed extensively with lysis buffer, eluted and subjected to SDS-PAGE, followed by western blot analysis with anti-SIRT1 antibodies (top panel). The amount of GST fusion proteins was visualized by coomassie blue staining (lower panel). (f) Top panel: A schematic diagram (not drawn to scale) of cortactin and various Myc-tagged cortactin deletion mutants. Bottom panels: 293T cells were co-transfected with Flag-SIRT1 and indicated various Myc-tagged cortactin constructs, respectively. After 36 h of transfections, cells were lysed and Flag-SIRT1 was pulled down by anti-Flag (M2) agarose beads, followed by western blotting with anti-Myc (upper panel) and anti-SIRT1 antibodies (middle panel). The expression of Myc-tagged cortactin constructs is shown in lower panel. In upper and lower panels, the arrows denote the protein expression bands from indicated Myc-tagged cortactin constructs. For panels e and f, the pull-down assay and co-precipitations had been performed at least three times.
cells leads to enhanced cell motility and invasion (Patel et al., 1998) . In MDA-MB-231 cells, an invasive breast cancer cell line, cortactin is associated with the invadopodium, a cortical structure that penetrates into the extracellular matrix during invasion and overexpression of cortactin in this cell line increases cell migration (Bowden et al., 1999) . Moreover, cortactin potentiates bone metastasis of breast cancer cells in nude mice (Li et al., 2001) . Lastly, recent findings demonstrate that fibrosarcoma cells deficient in cortactin have impaired cell migration and invasion, underscoring the role of cortactin in cell motility (Bryce et al., 2005) . Histone deacetylases (HDACs) are enzymes that catalyse the removal of the acetyl moieties from the e-amino group of the lysine residues in histone and nonhistone proteins (Cress and Seto, 2000; Grozinger and Schreiber, 2002; Blander and Guarente, 2004; Gregoretti et al., 2004; Glozak et al., 2005) . These enzymes are members of an evolutionary conserved protein superfamily (Leipe and Landsman, 1997) . On the basis of statistical analyses of the evolutionary relationship between all recognizable HDAC relatives, HDACs fall into four distinct classes (Gregoretti et al., 2004) . Class I consists of HDACs 1, 2, 3 and 8, and class II consists of HDACs 4, 5, 6, 7, 9 and 10. HDAC11 is the lone member of class IV. Class III HDACs (also referred as 'sirtuins') are homologs of yeast SIR2 (silent information regulator 2); and the mammalian members of this class are SIRT1, 2, 3, 4, 5, 6 and 7. In contrast with the other three classes of HDACs, the activity of the class III HDAC family is NAD þ -dependent. Class III HDACs convert acetyl lysine and NAD þ into O-acetyl-ADP-ribose and nicotinamide. Owing to their dependency on NAD þ , the activity of the class III HDACs is regulated by the NAD þ /NADH ratio, and thus is sensitive to the status of cellular metabolism. Nicotinamide, a product of the deacetylation reactions, inhibits the activity of the class III HDACs, whereas trichostatin A, an inhibitor of classes I, II and IV, does not.
Of the seven class III HDAC members, SIRT1 is the best-characterized sirtuin in mammalian cells. It is the (Guarente, 2005; Wolf, 2006) . However, the role of SIRT1 in tumorigenesis remains largely undefined. Our earlier studies have demonstrated that cortactin is a substrate for HDAC6 (Zhang et al., 2007) . Cortactin deacetylation enhances the ability of cortactin to bind F-actin by modulating a 'charge patch' in its repeat region, whereas acetylation of cortactin ablates the interaction between cortactin and F-actin, resulting in decreased cell migration. In this study, we show that SIRT1 binds to and deacetylates cortactin, whereas the histone acetyltransferase p300 acetylates cortactin. SIRT1 is able to effectively rescue the migratory defect in sir2a À/À mouse embryo fibroblasts (MEFs). In addition, we show that cortactin is overexpressed in breast cancer tissues and that hypoacetylated cortactin is more abundant in breast tumor tissues than in their normal counterparts. Collectively, our findings suggest a novel role for SIRT1 in tumor cell migration through the deacetylation of cortactin, implying a new function of SIRT1 in tumor invasion and metastasis.
Results

SIRT1 interacts with cortactin
Earlier we found that the class III HDAC inhibitor, nicotinamide, remarkably enhanced the acetylation of cortactin (Zhang et al., 2007) . This finding suggests that class III HDACs deacetylate cortactin. To test this idea, we first determined which sirtuins interact with cortactin. Bead-bound glutathione S-transferase (GST)-cortactin was incubated with lysates of 293T cells transfected with Flag-SIRT1, Flag-SIRT2, Flag-SIRT3, Flag-SIRT4, Flag-SIRT5, Flag-SIRT6 or Flag-SIRT7. GST-cortactin-sirtuin complexes were pulled down by the GST beads, and Flag-tagged SIRTs were detected by anti-Flag western blotting. As shown in Figure 1a , Flag-SIRT1 was the only sirtuin that was associated with GST-cortactin. (a) 293T cells were transfected with Myc-cortactin and HA-p300 as indicated. After 36 h of transfections, cells were lysed and anti-Myc immunoprecipitations were carried out, followed by western blot analysis with anti-acetyllysine antibodies (anti-Ack). The blot was then stripped and reprobed with anti-Myc antibodies. A direct anti-HA western blot analysis was performed to determine the expression of HA-p300. To confirm that p300 was active in this system, a western blot was also performed in the same extracts with an antibody specific for acetylated K382 of p53 and acetylated histone H3, respectively. Direct western blots for total p53 and histone H3 were also performed. (b) 293T cells were transfected with Myc-cortactin, HA-p300, p300 shRNA and control shRNA as indicated. Anti-Myc immunoprecipitates were western blotted with antibodies specific for either AcK or Myc. Levels of HA-p300 were determined by anti-HA antibodies. (c) Anti-cortactin immunoprecipitations were performed with p300 þ / þ and p300 À/À mouse embryo fibroblasts (MEFs), followed by a western blot analysis with anti-Ac-cortactin antibodies. The blot was then stripped and reprobed with anticortactin antibodies. A direct anti-p300 western blot analysis was performed with the same lysates and an anti-HSP60 western blotting analysis was carried out to ensure the equal loading of protein. (a-c) Left panel: A representative western blot. Right panel: amounts of acetylated cortactin were quantified by densitometric analysis of western blot using ImageQuant 5.2 software. All graphs represent data derived from at least three independent experiments. Error bars denote standard error of the mean (s.e.m.).
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We next tested whether SIRT1 and cortactin interact when they are coexpressed. Myc-cortactin was transfected into 293T cells with either Flag-SIRT1 or Flag-SIRT2, and Myc-immunoprecipitates were immunoblotted with anti-Flag antibodies. Similar to the results of the pull-down experiments, Myc-cortactin interacted with Flag-SIRT1 but not with Flag-SIRT2 in this coimmunoprecipitation analysis (Figure 1b) .
To determine whether SIRT1 is associated with cortactin under native conditions, co-immunoprecipitation of the endogenous protein from C13 cell lysate was performed. C13 cells are ovarian cancer surface epithelial cells expressing high levels of SIRT1 and cortactin (data not shown). As shown in Figure 1c , a fraction of SIRT1 could be co-precipitated with an anti-cortactin antibody, but not with control anti-Flag serum. To confirm this interaction, a reciprocal immunoprecipitation was carried out. Anti-SIRT1 antibody, but not preimmune serum, could pull-down cortactin in C13 cells as shown in Figure 1d . Thus, SIRT1 and cortactin indeed interact with each other in an ovarian cancer cell line.
To identify the SIRT1-binding region in cortactin, we used GST-coupled cortactin fusion proteins: cortactin full-length, cortactin NTA region, repeat region of cortactin and cortactin C-term to incubate with cell lysates from C13 cells. GST-cortactin-SIRT1 complexes were pulled down by the GST beads and endogenous SIRT1 that interacts with cortactin were detected by a western blotting analysis using anti-SIRT1 antibodies. As shown in Figure 1e , cortactin full-length and repeat region of cortactin are associated with SIRT1.
We next mapped the SIRT1-binding regions in cortactin by a co-transfection assay in 293T cells. As shown in Figure 1f , Flag-SIRT1 interacts with cortactin N-term, which contains NTA and repeat region, but not with NTA region alone. Taken together with the above GST pull-down experiment (Figure 1e ), we speculate that the cortactin repeat region is the SIRT1-binding domain. Collectively, our data show that similar to HDAC6, SIRT1 interacts specifically with the repeat region of cortactin. 
Cortactin acetylation is catalysed by p300
We identified earlier p300/CBP-associated factor (PCAF) as an acetyltransferase for cortactin (Zhang et al., 2007) . However, in PCAF À/À MEFs, the levels of acetylated cortactin are the same as those of PCAF þ / þ MEFs, implying that additional cortactin acetyltransferases exist (Zhang et al., 2007) . We used a candidate approach and tested multiple acetyltransferases including p300, Tip60 and HBO for their ability to acetylate cortactin ( Figure 2a and data not shown). As shown in Figure 2a , p300 dramatically enhanced the acetylation levels of Myc-cortactin when both were co-expressed in 293T cells. Under our experimental conditions, other acetyltransferases have no effect on cortactin acetylation 
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Y Zhang et al (data not shown). Activity of p300 was validated by its ability to acetylate Lys382 of p53 and core histone H3 (Figure 2a) . Moreover, expression of a short hairpin RNA (shRNA) to p300 (Open Systems, Huntsville, AL, USA) sharply decreased cortactin acetylation in 293T cells expressing Myc-cortactin and HA-p300 (Figure 2b ). To further determine whether acetylation of cortacin depends on the presence of p300, cortactin was immunoprecipitated from p300 þ / þ and p300
MEFs, followed by an anti-acetyllysine western blotting analysis. The acetylated levels of cortactin were considerably lower in p300 À/À MEFs than those in p300
MEFs (Figure 2c ). Taken together, p300 is one of the acetyltransferases and perhaps the only one required for cortactin acetylation in vivo.
SIRT1 deacetylates cortactin
To determine whether SIRT1 deacetylates cortactin, Flag-cortactin, HA-p300, Myc-SIRT1 and Myc-SIRT1(H363Y), which is a deacetylase-deficient mutant, were co-transfected into 293T cells as indicated in Figure 3a , and Flag immunoprecipitates were immunoblotted with an antibody to acetyl lysine (AcK). As shown in Figure 3a , expression of Myc-SIRT1, but not Myc-SIRT1(H363Y), reduced the amount of acetylated Myc-cortactin. To assess whether SIRT1 could deacetylate cortactin in vitro, the in vivo p300-acetylated Myccortactin was served as a substrate, which was incubated with recombinant SIRT1. The deacetylation ability of SIRT1 toward Ac-cortactin was determined by the in vitro deacetylation assay described in the Supplementary Materials. As shown in Figure 3b , SIRT1 was able to deacetylate cortactin in the presence of NAD þ in a dose-dependent manner, and this property was abrogated by the addition of the sirtuins inhibitor nicotinamide, suggesting that SIRT1 indeed deacetylates cortactin in vitro. Conversely, we inhibited SIRT1 catalytic activity by EX-527 (Solomon et al., 2006) , a novel, potent and specific small-molecule inhibitor of SIRT1, which has no effect on other sirtuins in ovarian cancer cell lines to examine its effect on cortactin acetylation. Consistent with the above finding, we saw greater amounts of acetylated cortactin in EX-527-treated C13 cells (Figure 3c ) and A2780cp cells (Figure 3d ). Taken together, our studies suggest that cortactin is a specific target for SIRT1 deacetylase activity.
SIRT1 stimulates cell migration
To investigate whether SIRT1 modulates cell motility, we treated OV2008 cells with the sirtuin inhibitor, nicotinamide, and performed a wound-healing experiment. Nicotinamide-treated cells migrated slower than that of vehicle-treated cells (Figure 4a ). Acetylation levels of cortactin were dramatically enhanced after nicotinamide treatment by a western blotting analysis using anti-acetyl cortactin antibodies (Figure 4a ). These data suggest that sirtuins could promote cell migration by deacetylating of cortactin. To further elucidate the roles of SIRT1 in cell motility, we examined the À/À MEFs were less motile than that of sir2a þ / þ MEFs. Moreover, the levels of acetylated cortactin were elevated in sir2a À/À MEFs, implying that SIRT1 is a deacetylase responsible for deacetylating cortactin. To determine whether the reduced migratory ability in sir2a À/À MEFs is because of the loss of sir2a, we introduced human SIRT1 into sir2a À/À MEFs and performed Transwell assays. As shown in Figure 4c , SIRT1 significantly restored migration properties of sir2a À/À MEFs. Therefore, our results indicate that SIRT1 promotes cell migration. To determine whether the deacetylation mimetic cortactin mutant can rescue sir2a À/À MEFs' migration deficiency,
Flag-9KR
β-Actin The effect of nicotinamide on cell migration was examined in wound-healing assays. Confluent OV2008 cells were scratched with a 10-ml pipette tip and photographed at time zero. Then nicotinamide was added to the culture medium at a final concentration of 20 mM. Photographs were taken 24 h later (left panel). OV2008 cells were treated with vehicle control or 20 mM nicotinamide for 24 h, at which time the acetylation of cortactin was determined by western blotting analysis using an anti-acetyl-cortactin antibody. The membrane was then stripped and reprobed with anti-cortactin antibodies to examine the levels of total cortactin (right panel). Amounts of acetylated cortactin from three independent western blots were quantified by densitometry (bar graph). Error bars show s.e.m. (b) Sir2a À/À mouse embryo fibroblasts (MEFs) have decreased cell migration. Sir2a þ / þ and sir2a À/À MEFs were serum-starved overnight and measured for migratory properties using Transwell assays. Migratory cells were stained (left panel) and quantified at OD 560 nm after extraction (middle panel). Error bars denote s.d. The levels of acetylated cortactin and sir2a in sir2a þ / þ and sir2a À/À MEFs were determined by western blotting analysis using indicated antibodies (right panel). Amounts of acetylated cortactin from three independent western blots quantified by densitometry (right bottom bar graph). 
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Flag-K9R was stably transfected into sir2a À/À MEFs. As shown in Figure 4d , the deacetylation mimetic cortactin mutant efficiently augmented the cell motility in sir2a
MEFs. Thus, our data further strengthen the notion that cortactin functions as a substrate and downstream effector of SIRT1 in regulating cell migration.
Acetylation of cortactin negatively regulates cell migration in ovarian and breast cancer cells
Our earlier studies demonstrated that cortactin acetylation affected cell migration in NIH 3T3 cells (Zhang et al., 2007) . To determine whether the reversible acetylation of cortactin functions in tumor cell migration, we stably transfected Flag-9KQ or Flag-9KR into ovarian or breast cancer cells and examined their effect on cell motility. Flag-9KQ was made by substituting nine acetylatable lysines in the repeat region of cortactin with glutamine to mimic the acetylated status of cortactin, whereas Flag-9KR was generated by mutating the same nine lysines to arginine to mimic the deacetylated status of cortactin (Zhang et al., 2007) . We generated stable clones in SKOV3 ovarian cancer cells that overexpress wild-type cortactin, named WT15, or an acetylation mimetic mutant of cortactin, named 9KQ44. We also established several MDA-MB-231-luc breast cancer cell clones that overexpress wild-type cortactin (WT15, WT11 and WT20), an acetylation mimetic mutant of cortactin (9KQ44, 9KQ15 and 9KQ30) or a deacetylation mimetic mutant of cortactin (9KR7 and 9KR16). As shown by Transwell assays, expression of wild-type cortactin or the deacetylation mimetic mutants increased migration as compared with cells expressing empty vector (Figures 5a and b) . In contrast, expression of the acetylation mimetic mutants substantially reduced migration. These results demonstrate that the hypoacetylated form of cortactin promotes cell migration, whereas the hyperacetylated form of cortactin attenuates cell migration in ovarian and breast cancer cells.
Cortactin is hypoacetylated in breast tumor tissues
Our earlier studies revealed that cortactin is an acetylated protein in vivo (Zhang et al., 2007) . To determine whether there is aberrant acetylation of cortactin in cancers, we examined cortactin acetylation in two types of breast tissue specimens: breast cancer tissues and their uninvolved benign counterparts. As shown in Figure 6a , the levels of acetylated cortactin were strikingly decreased in cases 159D and 261D; however, they were appeared at similar levels in other Deacetylation of cortactin by SIRT1 Y Zhang et al cases, but total cortactin levels were dramatically increased in malignant breast tissues. Therefore, after normalizing with the levels of cortactin in five out of eight pairs (159D, 163A, 172A, 261B and 429C), acetylated cortactin levels were significantly lower in breast cancer tissues as compared with their normal counterparts as shown in Figure 6b . Intriguingly, the levels of SIRT1 inversely correlated with the acetylated cortactin levels in four pairs (159D, 163A, 261B and 429C) of breast tissue specimens (Figure 6a ). Collectively, these studies suggest that deacetylated cortactin and high levels of SIRT1 are associated with breast tumorigenesis. SIRT1 overexpression may contribute to reduced cortactin acetylation level in breast tumors.
SIRT1 is present in the cytoplasm as well as in the nucleus in ovarian cancer specimens SIRT1 is mostly described as a nuclear protein, whereas cortactin is primarily localized in the cytoplasm. However, the extensive studies of SIRT1 localization in tumor cell lines and tumor specimens are not well documented. We have examined the SIRT1 expression in C13 and OV2008 ovarian cancer cell lines by immunofluorescence staining with anti-SIRT1 antibodies, a fraction of SIRT1 was found in the cytoplasm (Supplementary Figures S1 and S2 ). We next examined SIRT1 expression in ovarian cancer specimens and normal ovary samples by immunohistochemistry. As shown in Figure 7b , abundant SIRT1 was found in the cytoplasm of ovarian cancer cells, implying the role of SIRT1 with cortactin and cell migration. SIRT1 was also present in the cytoplasm and nucleus in normal ovarian surface epithelial cells (Figure 7a ), but was relatively weaker compared with SIRT1 staining in ovarian cancer samples ( Figure 7b ). Elevated nuclear SIRT1 staining in prostate cancer was recently reported (Huffman et al., 2007) , and a prostate cancer specimen served as a positive control for anti-SIRT1 antibody (Figure 7c ). An anti-mouse IgG immunohistochemistry staining with ovarian cancer specimen served as a negative control for mouse monoclonal anti-SIRT1 antibody (Figure 7d ). The percentages of cells expressing cytoplasmic or nuclear SIRT1 were examined in normal ovarian tissue and ovarian carcinoma samples by pathologist (Supplementary show that majority of cells express both cytoplamic and nuclear SIRT1 in normal ovarian and ovarian carcinoma samples.
Discussion
Mammalian SIRT1 is an NAD þ -dependent deacetylase, which is involved in a wide spectrum of biological processes, including stress responses, cellular metabolism, and possibly, aging and tumorigenesis. SIRT1 exerts its functions through diverse substrates, such as nuclear factor-kB, p53, Ku70, BCL6, PGC-1a, forkhead transcription factor (FOXO), MyoD and histone Luo et al., 2001; Bereshchenko et al., 2002; Ito et al., 2002; Fulco et al., 2003; Brunet et al., 2004; Cohen et al., 2004; Daitoku et al., 2004; Motta et al., 2004; Vaquero et al., 2004; van der Horst et al., 2004; Rodgers et al., 2005) . In the results presented above, we have added cortactin to this growing list. Given the fact that cortactin is intimately associated with cell migration and sir2a
À/À MEFs were less motile than that of their wild-type counterparts, our study provides the first indication that SIRT1 modulates cell motility. To examine whether SIRT1 expression is altered in human cancers, we have tested the expression levels of SIRT1 in breast and ovarian cancers. Consistent with the earlier studies that SIRT1 is overexpressed in cancer cell lines and various cancers (Huffman et al., 2007; Stu¨nkel et al., 2007) , we found that the levels of SIRT1 are elevated in both ovarian and breast cancers ( Figure 6 and data not shown). Interestingly, SIRT1 levels inversely correlate with the levels of acetylated cortactin in breast tissue specimens, further suggesting that SIRT1 is one of the deacetylases for cortactin in vivo.
SIRT1, although mainly localized in the nucleus, can be shuttled to the cytoplasm (Tanno et al., 2007) . A recent study showed that human SIRT1 is highly expressed in the cytoplasm in tissue samples from colon carcinoma patients (Stu¨nkel et al., 2007) . SIRT1 was present in the cytoplasm in pancreatic islet a and b cells (Moynihan et al., 2005) and was also found to be cytosolic in C2C12 myoblast cells after differentiation (Tanno et al., 2007) . The emerging roles of cytosolic SIRT1 were documented recently. Several lines of evidence showed that localization of SIRT1 in the cytoplasm is induced during apoptosis (Ohsawa and Miura, 2006; Jin et al., 2007) . In addition, Hallows et al. demonstrated that SIRT1 catalyses the deacetylation of Acetyl-CoA synthetases (AceCSs) in the cytoplasm (Hallows et al., 2006) . In this study, we found that SIRT1 is localized in both the nucleus and cytoplasm in OV2008 and C13 ovarian cancer surface epithelial cells (Supplementary Figures S1 and S2) . In ovarian cancer specimens, a large fraction of SIRT1 was found in the cytoplasm (Figure 7b and Supplementary Table 1) . It is very likely that cytoplasmic SIRT1 stimulates the migration of tumor cells. Further studies a SIRT1 nuclear import-deficient mutant on cell migration will reveal the cytoplasmic function of SIRT1 on cell motility.
We showed earlier that HDAC6 binds to and deacetylates cortactin (Zhang et al., 2007) . In addition, co-treatment with the classes I and II HDAC inhibitor, trichostatin A, and class III inhibitor, nicotinamide, synergistically increased the levels of acetylated cortactin. It is tempting to speculate that HDAC6 and SIRT1 might bind to and enhance each other's enzymatic activity. In fact, SIRT1 is targeted for acetylation in vivo (YY and WB, unpublished results). However, the deacetylases responsible for SIRT1 deacetylation are largely unknown. It is intriguing how these two deacetylases work on the same substrate, cortactin. Do they work cooperatively, redundantly or in other manners? Earlier, we showed that the suppression of the activities of HDAC6 and SIRT1 resulted in the robust induction of cortactin acetylation, whereas the inhibitor that suppressed either of the deacetylases caused a moderate increase of cortactin acetylation in HeLa cells (Zhang et al., 2007) . Consistent with the data, the levels of acetylated cortactin are only modestly enhanced in either HDAC6-or sir2a-null MEFs compared with their wild-type counterparts (Figure 4b ; Zhang et al., 2007) . Collectively, our data indicate the either HDAC6 or SIRT1 is able to bind and deacetylate cortactin independently, and both of them together confer the additive or synergistic enzymatic activity toward cortactin. Therefore, we propose that HDAC6 and SIRT1 deacetylate cortactin in a cooperative manner. However, as shown in Figure 4a , nicotinamide's effect on OV2008 cell migration and cortactin acetylation is evident, indicating that SIRT1 is dominant in this cell line. Given the fact that both SIRT1 and HDAC6 bind to the repeat region of cortactin, it is possible that SIRT1 and HDAC6 compete for cortactin deacetylation in OV2008 cells. It is conceivable that it depends on cell types whether HDAC6 and SIRT1 cooperatively or competitively deacetylate cortactin. Nevertheless, there is no doubt that this issue warrants further investigation.
It was documented that HDAC6 is associated with SIRT2 and SIRT2 also deacetylates cortactin in vivo (North et al., 2003; Zhang et al., 2007) . However, we failed to detect the association of SIRT2 and cortactin under our experimental conditions (Figure 1b) . Therefore, SIRT2 could either form a transit complex with cortactin or it deacetylates cortactin through other deacetylases. Although we captured the SIRT1/cortactin complex in C13 cells (Figure 1c) , the amount of SIRT1 that interacts with cortacin is very little. Given the fact that SIRT1 could efficiently deacetylate cortactin in vivo and in vitro (Figures 3a and b) , we speculate that SIRT1 either does not form a stable complex with cortactin or deacetylates cortactin by inhibiting p300 as we discussed later.
Earlier, we failed to detect the ability of p300 to acetylate cortactin in HeLa cells by co-transfection of HA-p300 and Myc-cortactin (Zhang et al., 2007) . However, in 293T cells, we were able to reproducibly monitor the enhanced acetylation cortactin by overexpression of p300. This discrepancy was probably because of the high transfection efficiency in 293T cells, which enabled to express high levels of p300. Nevertheless, the data that the levels of acetylation cortactin were decreased in p300-deficient cells equivocally demonstrated that p300 is at least in part responsible for acetylation cortactin (Figure 2c ). Several lines of evidence showed that SIRT1 physically interacts with p300 (Motta et al., 2004) . In addition, SIRT1 negatively regulates the p300 activity by deacetylating the lysine residues at positions 1020 and 1024, both of which reside in a key regulatory domain (Bouras et al., 2005) . Therefore, SIRT1 may exert two levels of regulation on the deacetylation of cortactin by not only directly deacetylating cortactin but also by inhibiting p300 activity and maintaining cortactin in a hypoacetylated state. p300 is a tumor suppressor gene (Iyer et al., 2004) . Mutations and deletions of p300 have been observed in a variety of cancers (Iyer et al., 2004) . Recent studies of p300-null HCT116 cells indicate that p300-null cells show loss of cell-to-cell adhesion, defects in cell-matrix adhesion and increased migration (Krubasik et al., 2006) . Our studies now show that p300 is responsible for acetylation of cortactin, thus providing mechanistic insights into enhanced cell migration in p300-null cells.
Protein post-translational modifications tend to work in concert at several levels on a given protein. Cortactin is phosphorylated by Src and other kinases. Moreover, phosphorylation of cortactin by c-Src is associated with hyaluronic acid-dependent ovarian tumor cell migration (Bourguignon et al., 2001) . It would be important to test whether acetylation affects phosphorylation or vice versa. An earlier study showed that the N-terminal domain of cortactin is essential for Src-targeted phosphorylation at the C terminus (Head et al., 2003) . As the acetylation primarily occurred within the N-terminal domain of cortactin, it is logical to speculate that acetylation in the N-terminal domain may influence Src-induced phosphorylation at the C terminus. This hypothesis remains to be further tested.
Apart from the role of cortactin in cell migration and invasion, cortactin also plays important roles in other cellular processes, such as vesicular transport, receptor downregulation, and so on (Cao et al., 2005; Kessels and Qualmann, 2005; Timpson et al., 2005) . It is very possible that cortactin acetylation might regulate these processes besides cell migration. In summary, our investigations on cortactin acetylation revealed a new function of SIRT1 in regulating cell migration and identify a novel target for HDAC inhibitor-based therapies.
Materials and methods
Reagents and plasmids
The following expression plasmids used in the experiments have been described earlier: Myc-cortactin, Myc-N-term, Myc-NTA, Myc-C-term (Zhang et al., 2007) , HA-p300 (Aizawa et al., 2004) , GST-cortactin, GST-NTA, GST-repeat, GST-Cterm (Zhang et al., 2007) , Flag-SIRT1-7 (North et al., 2003; Michishita et al., 2005) , Myc-SIRT1 (Langley et al., 2002) , GST-SIRT1 (Langley et al., 2002) and Myc-SIRT1(H363Y) (Langley et al., 2002) . Mouse monoclonal anti-cortactin antibody (4F11), rabbit polyclonal anti-SIR2 antibody, rabbit anti-acetyllysine antibody, rabbit polyclonal anti-Ac-histone H3 antibody and rabbit polyclonal anti-histone H3 antibody were purchased from Upstate (Millipore, Billerica, MA, USA). Rabbit monoclonal anti-SIRT1 antibody (E104) was purchased from Abcam Inc. (Cambridge, MA, USA). Rabbit polyclonal anti-Ac-cortactin antibody was developed by Upstate (Millipore). Mouse monoclonal anti-Flag antibody (M2) and mouse monoclonal anti-b-actin antibody were purchased from Sigma (St Louis, MO, USA). Rabbit polyclonal anti-Myc antibody (A-14) was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Rabbit polyclonal anti-p53 antibody was purchased from Becton, Dickinson and Company (BD) (Franklin Lakes, NJ, USA). Mouse monoclonal anti-HA antibody was purchased from Covance (Princeton, NJ, USA). Rabbit polyclonal antiacetylated Lys382-p53 antibody was purchased from Cell Signaling Technology (Beverly, MA, USA). Mouse monoclonal anti-SIRT1 antibody, 10E4, for immunohistochemistry analyses was generated by Dr Jiandong Chen. EX-527 was purchased from Tocris Bioscience (Ellisville, MO, USA). All other reagents were purchased from Fisher Scientific (Pittsburgh, PA, USA).
Cell culture, establishment of stable transfected cell lines and stable pools, immunoprecipitations and immunoblotting analyses, cell migration assay, immunohistochemistry, preparation of human tissue samples for western blotting analysis, wound-healing assay, in vitro deacetylation assay and purification of GST fusion protein methods are described in Supplementary Materials.
